Long-Term Evaluation of Infliximab in the Treatment of Persistently Active Juvenile Idiopathic Arthritis Refractory to Conventional Therapy. Reumatismo 2007, 59 (1), 50-56. https://doi.org/10.4081/reumatismo.2007.50.